This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walsh, K. M. Articles by Rothwell, C. E. Search for Related Content PubMed PubMed Citation Articles by Walsh, K. M. Articles by Rothwell, C. E. Social Bookmarking                         What's this?

Hepatic Effects in Beagle Dogs Administered Atorvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, for 2 Years

Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan

Charles E. Rothwell

Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan

The chronic toxicity of atorvastatin (AT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was evaluated in beagle dogs. Dogs were treated with 0, 10, 40, or 120 mg/kg of AT daily. Treatment lengths were 52 wk, 52 wk followed by 12 wk without drug, or 104 wk. Decreases in cholesterol levels were dose related and stable throughout the treatment period. Increases in alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were transient and dose related in severity at 40 mg/kg. Two dogs administered 120 mg/kg of AT daily were sacrificed moribund during the first 9 wk of treatment. Hepatic lesions were reversible with or without continued treatment and dose related in severity and distribution. Hepatic microgranulomas and hepatocellular degeneration were seen at the 120-mg/kg dose in dogs sacrificed before 53 wk. Before 53 wk, hepatocellular lipofuscin deposits were increased in dogs given 40 mg/kg of AT daily but were similar to controls after 12 wk without drug and after 104 wk of continuous treatment. Bile stasis occurred in dogs given 40 mg/kg of AT daily at all time points but was less severe after reversal and at week 104 compared with week 52.

Key Words: Lipid regulation • liver • cholesterol • microgranuloma • lipofuscin

References

• Alberts AW, MacDonald JS, Till AE, and Tobert JA (1989). Lovastatin. Cardiovasc. Drug Rev. 7: 89-109.
• Berry PH, MacDonald JS, Alberts AW, Molon-Noblot S., Chen JS, Lo Cyl, Greenspan MD, Allen H., Durand-Cavagna G., Jensen R., Bailly Y., Delort P., and Duprat P. (1988). Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. J. Pathol. 132: 427-443.[Abstract]
• Bocan Tma, Ferguson E., McNally W., Uhlendorf PD, Mueller SB, Dehart P., Sliskovic DR, Roth BD, Krause BR, and Newton RS (1992). Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123: 133-144.[Medline] [Order article via Infotrieve]
• Chapman BL, Hendrick MJ, and Washabau RJ (1993). Granulomatous hepatitis in dogs: Nine cases (1987-1990). J. Am. Vet. Med. Assoc. 203: 680-684.[Web of Science][Medline] [Order article via Infotrieve]
• Cheville NF (1983). Cell Pathology, 2nd ed. Iowa State University Press, Ames, pp. 155-158, 278.
• Dostal L., Juneau P., and Rothwell CE Semen analysis in a 2-year study with HMG-coA reductase inhibitor, atorvastatin, in beagle dogs. Manuscript in preparation.
• Gerson RJ, Allen HL, Lankas GR, MacDonald JS, Alberts AW, and Bokelman DL (1991). The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. Fundam. Appl. Toxicol. 16: 320-329.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, and Bokelman DL (1989). Animal safety and toxicology of simvastatin and related hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87: 28S-38S.[Medline] [Order article via Infotrieve]
• Harman D. (1990). Lipofuscin and ceroid formation: The cellular recycling system. Adv. Exp. Med. Biol. 266: 3-15.
• Hartman HA, Myers LA, Evans M., Robison RL, Engstrom RG, and Tse Rls (1996). The safety evaluation of fluvastatin, an HMG-coA reductase inhibitor, in beagle dogs and rhesus monkeys. Fundam. Appl. Toxicol. 29: 48-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Havel RJ (1992). Role of the liver in hyperlipidemia. Semin. Liver Dis. 12: 356-363.[Web of Science][Medline] [Order article via Infotrieve]
• Jolly RD and Dalefield RR (1990). Lipopigments in veterinary pathology: Pathogenesis and terminology. Adv. Exp. Med. Biol. 266: 157-167.
• Jones TW, Fisher LF, Meador VP, Perry DN, and Eacho PI (1996). Sterol-induced hepatic microgranulomas. Fundam. Appl. Toxicol. 30(1): 102 (abstract 522).[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lee WL (1995). Drug-induced hepatotoxicity. N. Engl. J. Med. 333: 1118-1127.[Free Full Text]
• MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S., Berry PH, Alberts AW, and Bokelman DL (1988). Preclinical evaluation of lovastatin. Am. J. Cardiol. 62: 16J-27J.[CrossRef][Medline] [Order article via Infotrieve]
• Mesfin GM, Higgins MJ, Thornburgh BA, Jones BW, Van de Giessen TL, and Sinha AJ (1992). Drug-induced hepatic microgranulomatosis in cynomolgus monkeys. Toxicol. Pathol. 20: 7-17.[Abstract/Free Full Text]
• Nakano S., Yada H., Irimura K., Asanoma H., Hirota T., and Terazawa K. (1992). A 52-week oral toxicity study of 6-amidino-2-naphthyl-4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) in dogs. J. Toxicol. Sci. 17: P163-P199.
• National Institutes of Health ( 1985). Animal Welfare Act, 1966, amended in 1970, 1976, and 1985, 9 CFR Parts 1, 2, and 3. Publication 86-23.
• Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, and Black DM (1995). Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682.[Abstract/Free Full Text]
• Okolicsanyi L., Lirussi F., Strazzabosco M., Jemmolo RM, Orlando R., Nassuato G., Muraca M., and Grepaldi G. (1986). The effect of drugs on bile flow and composition: An overview. Drugs 31: 430-438.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Philips MJ, Poucell S., and Oda M. (1986). Mechanisms of cholestasis. Lab. Invest. 54: 593-608.[Web of Science][Medline] [Order article via Infotrieve]
• Poole A., Betton GR, Salmon G., Sutton T., and Atterwill CK (1990). Comparative toxicology of temalastine. Fundam. Appl. Toxicol. 14: 71-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Robertson DG, Urda ER, Rothwell CE, and Walsh KM (1997). Atorvastatin is not cataractogenic in beagle dogs. Curr. Eye Res. 16: 1229-1235.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sigler RE, Dominick MA, and McGuire EJ (1992). Subacute toxicity of a halogenated pyrrole hydroxymethylglutaryl-coenzyme A reductase inhibitor in Wistar rats. Toxicol. Pathol. 20: 595-602.[Abstract/Free Full Text]
• Sliskovic DR, Roth BD, and Bocan Tma (1992). Tissue selectivity of HMG-CoA reductase inhibitors. Drug News Perspect. 5: 517-533.
• Smellie Was and Lorimer AR (1992). Adverse effects of the lipid-lowering drugs. Adverse Drug React. Toxicol. Rev. 11: 71-92.
• Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, and MacDonald JS (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J. Phannacol. Exp. Ther. 257: 1225-1235.
• Tarumi C., Matsunumo N. Miyakoshi N, Yamashita K., and Masuda H. (1989). Long term oral administration study of pravastatin sodium to beagles for 104 weeks. J. Toxicol. Sci. 14: 85-101.[Medline] [Order article via Infotrieve]
• Tobert JA (1987). New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76: 534-538.[Abstract/Free Full Text]
• U.S. Department of Health and Human Services ( 1985). Guide for the Care and Use of Laboratory Animals. Animal Resources Program, Division of Research Resources, National Institutes of Health, Bethesda, Maryland.
• Walsh KM, Albassam M., and Clarke DE (1996). Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-Coenzyme A reductase inhibitor, in beagle dogs. Toxicol. Pathol. 24: 468-476.[Abstract/Free Full Text]
• Willingham MC (1989). A role for intracellular traffic of HDL in cholesterol metabolism. Lab. Invest. 61: 253-254.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 4, 395-401 (1999)
DOI: 10.1177/019262339902700402


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. MacDonald and M. M. Halleck The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41. [Abstract] [PDF]

				B. K. Bernard, A. M. Hoberman, W. R. Brown, A. K. Ranpuria, and M. S. Christian Oral (Gavage) Two-Generation (One Litter Per Generation) Reproduction Study of Pentachlorophenol (Penta) in Rats International Journal of Toxicology, July 1, 2002; 21(4): 301 - 318. [Abstract] [PDF]

				L. A. Dostal, P. Juneau, and C. E. Rothwell Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin Toxicol. Sci., May 1, 2001; 61(1): 128 - 134. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walsh, K. M. Articles by Rothwell, C. E. Search for Related Content PubMed PubMed Citation Articles by Walsh, K. M. Articles by Rothwell, C. E. Social Bookmarking                         What's this?